Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$1.38B
EBITDA Margin
-10195.54%
TTM Avg
-87388.52%
3Y Avg
-48181.08%
5Y Avg
-32386.50%
Market Cap
$1.43B
EBITDA Margin
21.45%
TTM Avg
-50.92%
3Y Avg
-538.26%
5Y Avg
-378.46%
Market Cap
$1.32B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.44B
EBITDA Margin
36.35%
TTM Avg
36.35%
3Y Avg
36.35%
5Y Avg
36.35%
Market Cap
$1.46B
EBITDA Margin
3.56%
TTM Avg
3.76%
3Y Avg
3.79%
5Y Avg
3.46%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.40B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.38B | -10195.54% | -87388.52% | -48181.08% | -32386.50% |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 21.45% | -50.92% | -538.26% | -378.46% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.32B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.44B | 36.35% | 36.35% | 36.35% | 36.35% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 3.56% | 3.76% | 3.79% | 3.46% |
| GH Research PLC (GHRS)vs › | $1.47B | N/A | N/A | N/A | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 5.15% | 0.72% | -7.50% | -11313.48% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
